SOPHiA GENETICS (NASDAQ:SOPH) Sees Large Volume Increase – Still a Buy?

SOPHiA GENETICS SA (NASDAQ:SOPH) shares saw unusually-high trading volume on Tuesday . 1,310,764 shares changed hands during mid-day trading, an increase of 396% from the previous session’s volume of 264,333 shares.The stock last traded at $7.9040 and had previously closed at $7.86.

Analysts Set New Price Targets

Several research firms have recently weighed in on SOPH. HC Wainwright raised their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Trading Up 2.3%

The company’s 50-day moving average is $7.18 and its 200-day moving average is $5.76. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a market cap of $684.12 million, a price-to-earnings ratio of -7.09 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. On average, research analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Insider Activity at SOPHiA GENETICS

In other SOPHiA GENETICS news, CEO Jurgi Camblong sold 50,069 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $5.80, for a total value of $290,400.20. Following the transaction, the chief executive officer directly owned 3,601,493 shares in the company, valued at approximately $20,888,659.40. This trade represents a 1.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock in a transaction on Friday, August 7th. The shares were sold at an average price of $7.29, for a total value of $123,930.00. Following the completion of the sale, the insider directly owned 590,887 shares of the company’s stock, valued at $4,307,566.23. This trade represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 357,260 shares of company stock valued at $2,317,759 in the last 90 days. 4.88% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently added to or reduced their stakes in the company. AWM Investment Company Inc. bought a new stake in SOPHiA GENETICS during the 2nd quarter worth about $9,809,000. Principal Financial Group Inc. boosted its stake in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the 1st quarter worth approximately $2,157,000. Royce & Associates LP acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. Finally, Sei Investments Co. acquired a new stake in shares of SOPHiA GENETICS during the 1st quarter worth approximately $1,772,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.